Therapeutic Goods (Standard for MDMA) (TGO 112) Order 2024

The central concepts in TGO 112 are the distinction between the active ingredient (MDMA hydrochloride) and the finished product (MDMA hydrochloride product), the use of assay limits as quantitative legal thresholds, the incorporation of external pharmacopoeial standards by reference, and the concept of a standard under the Therapeutic Goods Act.

MDMA hydrochloride is defined chemically as 3,4-methylenedioxy-N-methylamphetamine hydrochloride with formula C11H15NO2, HCl. It is the active ingredient and the object of Part 2 of the instrument. An MDMA hydrochloride product is defined as a therapeutic good that contains MDMA hydrochloride as the active ingredient and is manufactured in a dosage form for human therapeutic use. Section 11 restricts authorised products further by requiring that the product must contain MDMA hydrochloride as the only active ingredient and must be manufactured in the dosage form of a capsule for oral administration. This is a deliberate narrowing: the standard does not contemplate tablets, lozenges, liquids, injectables, or transdermal forms. Only capsules are permitted.

Assay limits are the quantitative boundaries within which the substance or product must fall. For the raw substance, the 98.0% to 102.0% range is standard for pharmaceutical grade active ingredients. The chloride assay (15.3% to 15.9%) is a stoichiometric check that the hydrochloride salt is present in the correct proportion. For finished products, the 90.0% to 110.0% range reflects the additional variability introduced by formulation and manufacturing of dosage forms. All assay tests use Ph Eur 2.2.29, which is the European Pharmacopoeia method for liquid chromatography, unless otherwise specified.

The instrument incorporates several external documents by reference: the United States Pharmacopeia-National Formulary (USP), the European Pharmacopoeia (Ph Eur), the ICH Q3D guideline document (as in force from time to time), and the Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TGO 101) Order 2019 for the definition of capsule. This means the content of those external standards is legally operative, but they are not reprinted in TGO 112. Users must access them separately, which imposes a practical compliance cost for obtaining current versions.

A standard under section 10 of the Act is a legislative instrument that sets requirements for therapeutic goods. Goods that do not comply with an applicable standard are non-complying and cannot be imported, exported, supplied, or manufactured without breaching the Act. The standard also interacts with the manufacturing licence framework: section 13(2) links the extemporaneous compounding exemption to testing having occurred at a site covered by a manufacturing licence, so the exemption does not relieve the compounder of the need for licensed premises.

TGO 112 directly affects several categories of parties, but the scope may be narrower than casual observers assume. It does not affect prescribers, patients, or the general public in any direct operational sense. It is an instrument about chemistry, not about clinical practice or access.

The primary affected parties are sponsors of MDMA hydrochloride products. A sponsor under the Act is the person who imports, exports, or arranges for the supply of therapeutic goods. For MDMA products, this is likely to be a pharmaceutical company or a licensed importer that holds a product registration or an approved access pathway such as the Authorised Prescriber Scheme or the Special Access Scheme. The sponsor is responsible for ensuring that every batch of imported or locally manufactured MDMA hydrochloride and every batch of capsules meets the assay limits, passes the Schedule 1 and Schedule 2 tests, and bears a label complying with section 14.

Manufacturers of MDMA hydrochloride and MDMA hydrochloride products are also directly affected. A manufacturer producing the raw active ingredient must ensure it meets the Part 2 requirements. A manufacturer producing capsules must comply with Part 3. The instrument effectively mandates that only capsule formulations are permissible, which constrains manufacturing flexibility. Manufacturers must have access to the Ph Eur test methods and the ICH Q3D guidelines, and must be able to perform or contract for the specified analytical tests including liquid chromatography, heavy metals analysis, residual solvents by gas chromatography, water content by Karl Fischer, and disintegration testing.

Pharmacists who extemporaneously compound MDMA hydrochloride capsules for individual patients are partially affected. They are exempt from the Schedule 2 tests (average content, disintegration, related substances, residual solvents, uniformity of dosage units) if the active ingredient they use was tested per section 9 at a site covered by a manufacturing licence. However, they are not exempt from the labelling requirements in section 14. Section 14(1) explicitly excludes extemporaneously compounded products from the mandatory labelling list, but the exclusion is permissive: it says the label need not contain those items, it does not prohibit including them. This creates a situation where compounded products have no mandatory labelling content but still must comply with section 14(2) requiring English, legible, durable, and not obscured.

Importers and exporters are affected because a non-complying standard under the Act is a strict liability offence for import and export when the goods are included in the Register. For unapproved goods accessed through the Special Access Scheme or Authorised Prescriber Scheme, the standard still applies because it is a quality standard, not a registration standard. Goods not meeting the standard cannot be lawfully imported even for unapproved use under those pathways.

The TGA itself is affected in its enforcement and compliance role. The standard gives the TGA clear quantitative benchmarks against which to assess product quality. A batch that falls outside the 90.0% to 110.0% assay range is objectively non-complying, reducing enforcement ambiguity.

The instrument imposes duties but confers no explicit rights on regulated parties. All duties are framed as obligations that must be satisfied for the goods to be compliant.

The central duty on any person who imports, exports, manufactures, or supplies MDMA hydrochloride or MDMA hydrochloride products is to ensure that the goods meet the assay limits and pass the specified tests. For MDMA hydrochloride, section 8 imposes two assay limits: purity not less than 98.0% and not more than 102.0% on an anhydrous basis, and chloride content not less than 15.3% and not more than 15.9%. Section 9 requires compliance with each item in Schedule 1 using the stated test method. This is a strict obligation: there is no margin of error, no grace period, and no mechanism for waiving a failed result.

For MDMA hydrochloride products, section 11 imposes two structural duties: the product must contain MDMA hydrochloride as the only active ingredient, and it must be manufactured as a capsule for oral administration. A sponsor cannot supply MDMA in tablet form under this standard, even if the tablets otherwise pass all assay limits. Section 12 imposes a pooled-sample assay duty: the average content of 20 or more capsules must fall between 90.0% and 110.0% of the stated content. This is a batch-level obligation, not a per-capsule obligation, though the uniformity of dosage units test in Schedule 2 item 5 partially addresses intra-batch variation.

Section 13(1) imposes the duty to comply with Schedule 2 tests. Section 13(2) provides a limited exemption: the schedule 2 tests do not apply to extemporaneously compounded products if the MDMA hydrochloride used was tested per section 9 at a site covered by a Part 3-3 manufacturing licence. This is a conditional exemption, not a blanket one. The compounder must have traceability evidence that the active ingredient batch was tested at a licensed site. The exemption also only covers the Schedule 2 tests; the product still must satisfy section 11 (capsule only, sole active ingredient) and section 12 (assay limits) applies on its own terms to all MDMA hydrochloride products, with no exception for extemporaneous compounding.

Section 14 imposes labelling duties. For products that are not extemporaneously compounded, the label must contain ten information items: product name, active ingredient name, quantity in mg, dosage form, quantity of product, batch number with prefix, expiry date with prefix, sponsor name, sponsor contact details (including a physical address in Australia, not a PO Box), and storage conditions. For extemporaneously compounded products, there is no mandatory list, but the general duties in section 14(2) still apply: any information that is on the label must be in English, legible, clearly visible, not obscured, and durable.

The instrument does not create any duties regarding prescribing, patient consent, monitoring, adverse event reporting, storage conditions beyond labelling, or disposal. Those matters are left to other instruments including the Poisons Standard, state and territory drugs and poisons legislation, and the Act itself.

TGO 112 does not itself create penalties. It is a standard made under section 10 of the Therapeutic Goods Act 1989, and the enforcement provisions are those of the Act. Non-compliance with the standard makes the goods non-complying therapeutic goods, which triggers a cascade of legal consequences under the Act.

Under the Act, it is an offence to import, export, manufacture, or supply non-complying therapeutic goods. The penalties for individuals can include fines of up to 5,000 penalty units per offence (currently over AUD 1.5 million) and/or imprisonment for up to five years for aggravated offences, with higher penalties for body corporates. Strict liability applies to some provisions, meaning the prosecution may not need to prove intent, only that the goods did not comply.

The practical enforcement mechanism is likely to be the TGA's quality surveillance program. The TGA can request samples of MDMA hydrochloride or MDMA hydrochloride products from sponsors or manufacturers, test them against the TGO 112 requirements using the specified Ph Eur methods, and take regulatory action if the goods fail. The TGA can also require a recall of non-complying batches, cancel or suspend product registrations, and issue infringement notices with civil penalties.

Because the standard uses objective numerical limits (e.g., purity between 98.0% and 102.0%, disintegration within 30 minutes), there is limited room for interpretive dispute. A result of 97.9% purity is a failure, not a borderline pass. This gives the TGA a strong enforcement position. It also creates a compliance risk for manufacturers whose analytical methods have measurement uncertainty that approaches the limits.

The exemption for extemporaneously compounded products in section 13(2) does not create immunity from enforcement. It only removes the obligation to perform the Schedule 2 tests. The compounder still must ensure the product meets section 11 and section 12, and the burden of proving the exemption applies (that the active ingredient was tested at a licensed site per section 9) rests with the person claiming the exemption.

The TGA also has powers under the Act to issue directions, seek injunctions, and impose conditions on manufacturing licences. A manufacturer that repeatedly produces non-complying MDMA hydrochloride could face suspension or cancellation of its licence under Part 3-3.

TGO 112 sits within a larger regulatory architecture for MDMA in Australia. It does not operate in isolation, and understanding its interactions is critical for anyone handling these goods.

The primary interaction is with the Therapeutic Goods Act 1989 itself. TGO 112 is a legislative instrument made under section 10 of that Act, so it has the legal status of a standard. Goods that do not comply with the standard are non-complying therapeutic goods under subsection 3(1) of the Act. This means all the Act's provisions about import, export, manufacture, supply, advertising, and post-market monitoring apply with the standard as the benchmark for compliance.

The standard interacts with the Therapeutic Goods (Standard for Tablets, Capsules and Pills) (TGO 101) Order 2019 because TGO 112 uses the definition of capsule from that instrument. TGO 101 sets its own standards for capsules including tests for uniformity of mass, disintegration, and dissolution. However, TGO 112 is the more specific standard for MDMA products and its Schedule 2 tests likely override the equivalent TGO 101 tests to the extent of any inconsistency, though the instrument does not explicitly state this. A prudent compliance approach would be to meet both standards.

The instrument interacts with the Regulations, specifically Schedule 5 items dealing with exempt goods and Schedule 5A items dealing with goods that are not subject to certain provisions. Section 6(2) excludes from the standard's application goods covered by Schedule 5 item 1 and certain Schedule 5A items (3, 4, 8, 10, 11, or 12) subject to their conditions. These exclusions likely cover certain low-risk or specially approved goods, but the detail is in the Regulations themselves, not in TGO 112.

The standard interacts with the Poisons Standard (the SUSMP). MDMA is currently in Schedule 9 (prohibited substance) with certain exceptions for approved therapeutic use. TGO 112 does not change scheduling. Access to MDMA for therapeutic use still requires compliance with state and territory drugs and poisons legislation, the Authorised Prescriber Scheme, the Special Access Scheme, or a clinical trial notification/approval.

The standard interacts with the Customs (Prohibited Imports) Regulations because MDMA is a border-controlled drug. Importation requires both TGA approval and a permit from the Department of Health. TGO 112 does not confer import permission; it only sets quality standards once import is otherwise lawful.

The ICH Q3D guideline is incorporated by reference as in force from time to time. This means that if the ICH updates Q3D, the standard in TGO 112 updates automatically without amendment to the instrument. Users must monitor ICH publications to remain compliant.

State and territory drugs and poisons legislation also governs the possession, supply, prescribing, and administration of MDMA. TGO 112 is not a prescribing or access instrument. It does not authorise a doctor to prescribe or a pharmacist to dispense. Those authorisations come from separate state and territory frameworks that interact with Commonwealth therapeutic goods law through a combination of referral powers and cooperative arrangements.

TGO 112 is a new instrument made on 19 August 2024, signed by Tracey Duffy as delegate of the Minister for Health and Aged Care, and it commences on 6 January 2025. It has no amendment history because it has not yet commenced as of the date of this analysis. The commencement table in section 2 confirms that the whole instrument commences on 6 January 2025 with no staged or partial commencement.

The instrument does not amend or repeal any existing standard. It is a standalone standard that adds to the body of TGO instruments. It does not supersede TGO 101, which continues to apply to capsules generally. It does not apply to any other active ingredients or dosage forms. It is specific to MDMA hydrochloride and MDMA hydrochloride capsules.

The absence of amendment history is significant for compliance purposes because there is no transition period, no grandfathering of existing stock, and no phasing in of requirements. From 6 January 2025, every batch of MDMA hydrochloride and every batch of MDMA hydrochloride products must comply. Manufacturers and sponsors cannot rely on prior testing protocols or earlier purity standards. Any existing inventory that does not meet the standard must be quarantined and cannot be supplied.

Future amendments could occur through the same mechanism: a new TGO made under section 10 of the Act, or an amendment to TGO 112 itself. Given the current political and regulatory attention on MDMA-assisted therapy, there is a real possibility that the standard may be amended to add additional dosage forms (e.g., tablets or oral solutions) or to tighten assay limits as more manufacturing data becomes available. Users should monitor the Federal Register of Legislation for amendments.

A notable structural feature is that the instrument incorporates the ICH Q3D guideline as in force from time to time, which is a dynamic reference. This means that if the ICH adjusts permissible limits for elemental impurities, those changes automatically flow into the Australian standard without any amendment to TGO 112. This is a practical approach that avoids repeated rulemaking, but it also means that a sponsor could face a sudden compliance gap if ICH Q3D tightens limits and their existing batch was manufactured to older, more lenient limits.

There is no litigation history for TGO 112 because it has not yet commenced. The instrument has not been challenged in court, and there are no reported decisions interpreting its terms. This section addresses the likely contours of future litigation rather than past decisions.

TGO 112 is a legislative instrument made under delegated authority. It could be challenged on grounds of procedural ultra vires if the delegate lacked authority, or substantive ultra vires if it goes beyond what section 10 of the Act permits. Section 10 allows the Minister or delegate to set standards for therapeutic goods. TGO 112 appears squarely within that power. A challenge would need to argue that the standard is unreasonable, arbitrary, or not authorised by the Act, which is a high bar.

More likely litigation would involve enforcement actions under the Act where the TGA alleges non-compliance with TGO 112. A defendant could argue that the test method was improperly applied, that the sample was not representative, that the Ph Eur method was incorrectly performed, or that the incorporation by reference of ICH Q3D or Ph Eur monographs was not properly notified. The instrument's use of objective numerical limits (98.0% to 102.0%, 15.3% to 15.9%) reduces the scope for factual dispute, but analytical chemistry always carries measurement uncertainty and methodological disagreements.

The automatic updating of ICH Q3D in force from time to time could face a legal challenge under the Legislation Act 2003 on grounds that it amounts to an impermissible incorporation of a non-legislative document as amended from time to time. The Legislation Act permits incorporation of documents as in force at a particular time but is more restrictive about dynamic incorporation. The instrument expressly uses the phrase as in force from time to time, which is a deliberate choice that invites scrutiny. If a court found this dynamic incorporation invalid, the reference to ICH Q3D might be read as referring to the version in force at the date of the instrument, which would create ambiguity about which limits apply.

The definition of capsule via TGO 101 could also be litigated if there is a dispute about whether a particular dosage form falls within that definition. TGO 101 may contain its own specifications for capsule shell composition, size, or testing that could affect compliance with TGO 112.

Given the high regulatory stakes and the limited number of sponsors expected to handle MDMA products, litigation is unlikely to be frequent. The TGA and industry participants will likely resolve disputes through administrative processes before they reach court.

Several provisions in TGO 112 are easy to overlook or misinterpret, particularly for those who approach it expecting a familiar pharmaceutical standard.

The most significant surprise is that section 11(b) restricts MDMA products to capsules for oral administration only. No other dosage form is permitted. A sponsor who develops MDMA tablets, lozenges, sublingual films, or injectable solutions cannot supply them under this standard. They would need a separate TGO or an exemption. This is a substantial constraint on pharmaceutical development and may catch companies accustomed to flexible formulation pathways.

The pooled sample assay requirement in section 12 requires not fewer than 20 capsules to be pooled and tested together. The average content must be 90.0% to 110.0% of stated content. This is not a per-capsule limit; individual capsules could be outside that range as long as the pool average is within it. However, the uniformity of dosage units test in Schedule 2 item 5 requires compliance with Ph Eur 2.9.40, which imposes per-unit limits on variation. A batch could pass the pooled assay but fail uniformity. Both must be satisfied.

The extemporaneous compounding exemption in section 13(2) is narrower than it first appears. It only exempts from the Schedule 2 tests. It does not exempt from section 11 (capsule only, sole active ingredient) or section 12 (pooled assay limits). The compounder must also prove that the MDMA hydrochloride used was tested per section 9 at a licensed site. If the compounding pharmacy tests its own active ingredient in-house, the section 9 tests must be conducted at a site covered by a manufacturing licence. Many compounding pharmacies may not hold such a licence for their analytical facilities, meaning they cannot rely on the exemption unless they send samples to a licensed external laboratory.

The labelling requirements in section 14(1) apply to products other than those extemporaneously compounded by a pharmacist for a particular patient. The exclusion is specific: it applies only to compounding for a particular patient, not to compounding for stock or for clinical trial use. A pharmacy that compounds MDMA capsules in anticipation of prescriptions or for a clinical trial must comply with the full labelling requirements. The exclusion also does not cover the section 14(2) requirements for English language, legibility, visibility, and durability even for compounded products.

The contact details of the sponsor must include a physical address in Australia that is not a post office, cable, telegraphic, or code address. A PO Box is insufficient. This catches offshore sponsors who might use a mail forwarding service or a lawyer's office as their Australian address. The address must be a physical premises where the sponsor can be contacted.

The instrument uses as in force from time to time for the ICH Q3D guideline. This means if ICH Q3D updates become more stringent, existing stock could become non-compliant even if it was tested against the earlier version. There is no transitional provision grandfathering batches tested before the guideline update. Sponsors must continuously monitor ICH publications.

The tests for related substances reference Ph Eur 5.10 for limits. Ph Eur 5.10 addresses control of impurities in substances for pharmaceutical use and sets general limits and reporting thresholds. But the instrument does not specify which Ph Eur monograph or general chapter applies as the source of the individual impurity limits for MDMA. It simply says not more than the limits specified in Ph Eur 5.10. Users must interpret whether this means the general limits in Ph Eur 5.10, or whether the specific limits for MDMA from a Ph Eur monograph (if one exists) are incorporated. This ambiguity could create disagreement between a manufacturer and the TGA.

Compliance requires a systematic approach spanning quality control, documentation, labelling, and ongoing monitoring. The following steps are grounded in the instrument's provisions and the broader Therapeutic Goods Act framework.

First, determine whether you handle MDMA hydrochloride (the raw active ingredient) or MDMA hydrochloride products (capsules), or both. Part 2 applies to the substance, Part 3 applies to products. If you import or manufacture the raw substance and also formulate capsules, you must comply with both Parts. If you only import finished capsules, you must ensure your overseas manufacturer complies with both Parts and that you have evidence of that compliance.

For MDMA hydrochloride, establish a quality control protocol that tests every batch against the six Schedule 1 items: heavy metals per Ph Eur 2.4.20 with ICH Q3D limits, purity of chloride per Ph Eur 2.2.29 between 15.3% and 15.9%, purity of MDMA hydrochloride per Ph Eur 2.2.29 between 98.0% and 102.0% on an anhydrous basis, related substances per Ph Eur 2.2.29 not exceeding Ph Eur 5.10 limits, residual solvents per Ph Eur 2.4.24 not exceeding Ph Eur 5.4 limits, and water content per Ph Eur 2.5.12 not more than 2.0%. Each test must use the specified compendial method; alternative validated methods are not permitted unless they are the specified method. Ensure your laboratory holds the current version of each Ph Eur chapter and the ICH Q3D guideline.

For MDMA hydrochloride products, establish a protocol that tests every batch against the five Schedule 2 items: average content per Ph Eur 2.2.29 on a pooled sample of not fewer than 20 capsules between 90.0% and 110.0% of stated content, disintegration per Ph Eur 2.9.1 or USP 701 within 30 minutes, related substances and residual solvents using the same methods as for the active ingredient, and uniformity of dosage units per Ph Eur 2.9.40. The uniformity test requires either mass variation or content uniformity; choose the method appropriate to your formulation but apply the limits in Ph Eur 2.9.40 strictly.

For labelling of non-extemporaneous products, include all ten items in section 14(1) in English, legible, clearly visible, not obscured, and durable. Use the specified prefixes for batch number and expiry date. The expiry date prefix list in the definitions is non-exhaustive but provides safe examples; using any other prefix carries risk if the TGA does not consider it to clearly indicate the expiry date. The sponsor's contact details must include a physical Australian address, not a PO Box.

If you are a pharmacist extemporaneously compounding MDMA capsules for a particular patient, document that the MDMA hydrochloride used was tested per section 9 at a site covered by a manufacturing licence. Retain certificates of analysis and evidence of the testing site's licence. Do not assume you are exempt from section 12 (assay limits) or section 11 (capsule only, sole active ingredient). Also comply with section 14(2) for any labelling you do apply, even though the mandatory list does not apply.

Review your supply chain contracts. Ensure your overseas manufacturers of MDMA hydrochloride and MDMA capsules know they must comply with TGO 112. The standard applies to goods imported into Australia, so foreign manufacturers need to understand the Australian-specific assay limits and test methods, which may differ from those in other jurisdictions.

Establish a change monitoring process for the ICH Q3D guideline, Ph Eur monographs, and Ph Eur general chapters. Because these are incorporated as in force from time to time, a revision to ICH Q3D could render your existing stock non-compliant overnight. If you have stock held in Australia at the time of a revision, you need a plan to test it against the updated limits.

Finally, ensure your manufacturing licence covers the activities you perform. Section 13(2) links the compounding exemption to testing at a site covered by a manufacturing licence granted under Part 3-3 of the Act. If you hold a manufacturing licence, confirm that it expressly covers the types of testing you conduct for MDMA hydrochloride and that the site is listed on the licence.